As onco-miR, it targets TRIM21 during BC progression [58]; miR-494-3p downregulation inhibits malignant behaviour of BC cells in vitro [59]. As oncosuppressor-miR, it inhibits BC cell mammospheres-forming capability and decreases tumorigenicity [60]. The gene discussed is TRIM21; the disease is breast cancer.